Short Interest in Mainz Biomed NV (NASDAQ:QUCY) Decreases By 85.5%

Mainz Biomed NV (NASDAQ:QUCY) saw a significant decrease in short interest in May. As of May 29th, there was short interest totaling 1,522,115 shares, a decrease of 85.5% from the May 14th total of 10,530,990 shares. Approximately 10.7% of the shares of the stock are sold short. Based on an average daily volume of 15,034,560 shares, the days-to-cover ratio is currently 0.1 days.

Mainz Biomed Stock Performance

QUCY traded down $0.04 during trading on Wednesday, hitting $2.00. 245,652 shares of the stock were exchanged, compared to its average volume of 10,334,215. The stock has a 50 day moving average price of $1.38. The firm has a market capitalization of $29.31 million, a price-to-earnings ratio of -0.04 and a beta of 2.22. Mainz Biomed has a 1 year low of $0.30 and a 1 year high of $4.93.

Mainz Biomed (NASDAQ:QUCY) last issued its earnings results on Tuesday, March 31st. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.13 million during the quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Weiss Ratings raised shares of Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Maxim Group cut Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.